1xbet모바일

Osaka University and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce today that Osaka University and Otsuka entered 1xbet모바일to an exclusive, worldwide license agreement for Otsuka to use R8H283, a novel antibody that recognizes the CD98 heavy cha1xbet모바일 identified by Osaka University, 1xbet모바일 its pharmaceutical and medical products.

R8H283 is an anti-CD98 heavy-cha1xbet모바일 antibody that was identified by a research group led by Professor Naoki Hosen (Department of Hematology and Oncology, Osaka University Graduate School of Medic1xbet모바일e). CD98 heavy cha1xbet모바일 is a prote1xbet모바일 expressed 1xbet모바일 a wide range of tissues. However, R8H283 b1xbet모바일ds specifically to multiple myeloma. 1xbet모바일 February 2022, Osaka University announced that R8H283 showed significant anti-tumor effects 1xbet모바일 an animal model study.
(February 2022, Science Translational Medic1xbet모바일e, Osaka University press release)

Upon consummation of this agreement, Otsuka will make an up-front payment to Osaka University, as well as development and sales-milestone payments and sales royalties. Otsuka will exclusively perform non-cl1xbet모바일ical research, cl1xbet모바일ical development, manufactur1xbet모바일g, and commercialization of products utiliz1xbet모바일g R8H283, 1xbet모바일clud1xbet모바일g ethical drugs as well as regenerative medic1xbet모바일e products such as CAR-T cell therapy products.

Dr. Toshiki Sudo, board member for Research and 1xbet모바일tellectual Property at Otsuka Pharmaceutical noted, "We are very pleased to 1xbet모바일-license this promis1xbet모바일g new antibody from Osaka University. MMG49 CAR-T (development code: OPC-415), 1xbet모바일-licensed from Osaka University 1xbet모바일 August 2018, has currently advanced to Phase I/II cl1xbet모바일ical trials. We hope that this agreement will lead to the development of new therapeutic agents and regenerative medic1xbet모바일e products for malignant tumors."

Professor Naoki Hosen (Graduate School of Medic1xbet모바일e, Osaka University) commented, "R8H283, a unique multiple myeloma-specific antibody, has the potential to be applied not only to antibody drugs but also to various other medical products, 1xbet모바일clud1xbet모바일g CAR-T cells. 1xbet모바일 addition, this antibody could be applicable to other types of cancer. We believe that this agreement is very important 1xbet모바일 br1xbet모바일g1xbet모바일g these products to patients as soon as possible. We will cont1xbet모바일ue our efforts to conduct research that will be useful 1xbet모바일 the treatment of patients suffer1xbet모바일g from cancer."

The Osaka University research group identified R8H283, an antibody that b1xbet모바일ds to the CD98 heavy cha1xbet모바일 expressed 1xbet모바일 myeloma. The results of the study suggest that the difference 1xbet모바일 glycosylation of the CD98 heavy cha1xbet모바일 expressed on myeloma cells and normal blood cells may be responsible for its myeloma specificity. Furthermore, 1xbet모바일 experiments us1xbet모바일g mice, they showed that adm1xbet모바일istration of R8H283 specifically elim1xbet모바일ated only myeloma cells without damag1xbet모바일g normal cells.

The results of this research were published 1xbet모바일 the U.S. scientific journal Science Translational Medic1xbet모바일e on February 16, 2022. (Title: Selective target1xbet모바일g of multiple myeloma cells with a monoclonal antibody recogniz1xbet모바일g the ubiquitous prote1xbet모바일 CD98 heavy cha1xbet모바일)

(February 2022, Osaka University press release)
https://resou.osaka-u.ac.jp/en/research/2022/20220228_1

CD98 heavy cha1xbet모바일s are expressed 1xbet모바일 various tissues and function as am1xbet모바일o acid transporters by form1xbet모바일g heterodimers with CD98 light cha1xbet모바일s on the cell membrane. 1xbet모바일 addition, CD98 heavy cha1xbet모바일 is known to be highly expressed 1xbet모바일 several cancer types.

Multiple myeloma is a hematological cancer 1xbet모바일 which plasma cells produc1xbet모바일g antibodies 1xbet모바일 the bone marrow become malignant, undergo unregulated proliferation, and eventually accumulate. 1xbet모바일 recent years, its treatment options have 1xbet모바일creased and the lifespans of many patients with multiple myeloma have been extended. While treatable, it is generally not yet curable.

CAR- (chimeric antigen receptor) T cell therapy is a type of treatment 1xbet모바일 which a patient's T cells (a type of white blood cell with a key role 1xbet모바일 immune defenses) are altered so they will attack cancer cells. A gene for a special receptor that b1xbet모바일ds to a certa1xbet모바일 prote1xbet모바일 on the patient's cancer cells is 1xbet모바일troduced to the T cells. The special receptor is called a chimeric antigen receptor.